Prévention des métastases hépatiques dans les cancers du côlon opérés radicalement.

Translated title of the contribution: Prevention of hepatic metastases in radically operated colonic cancers

S. Rea, F. Recchia, L. Belli, M. L. Jaffrain-Rea

Research output: Contribution to journalArticle

Abstract

The prognosis of colon cancer, after curative resection, is mainly related to the outcome of metastases, and especially of liver metastases. It is generally accepted that adjuvant medical therapy is important in order to prevent the incidence of metastatic recurrences. The aim of the present review is to analyse the conclusions of the main recent randomized trials assessing the comparative value of different adjuvant protocols. The results obtained using either systemic infusion, the classical one, or intraportal infusion, which is mainly designed to prevent liver metastases, are reported. On the basis of the review, we can conclude that: adjuvant chemotherapy using combined drugs (MF, MOF) did not prove to be more active than 5-FU alone. The beneficial action of a combined 5-FU + levamisole regimen has been clearly demonstrated for patients with a Dukes C tumour. According to a unique and limited trial, intraportal adjuvant therapy has been shown to be effective for patients with Dukes B tumours, but this remains to be confirmed. On the basis of the present data, new adjuvant programs using combined chemotherapeutic and immunotherapeutic coupounds, and combined systemic and loco-regional infusion, could be developed.

Original languageFrench
Pages (from-to)306-312
Number of pages7
JournalAnnales de Chirurgie
Volume45
Issue number4
Publication statusPublished - 1991

Fingerprint

Colonic Neoplasms
Neoplasm Metastasis
Fluorouracil
Liver
Levamisole
Adjuvant Chemotherapy
Neoplasms
Recurrence
Incidence
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery

Cite this

Rea, S., Recchia, F., Belli, L., & Jaffrain-Rea, M. L. (1991). Prévention des métastases hépatiques dans les cancers du côlon opérés radicalement. Annales de Chirurgie, 45(4), 306-312.

Prévention des métastases hépatiques dans les cancers du côlon opérés radicalement. / Rea, S.; Recchia, F.; Belli, L.; Jaffrain-Rea, M. L.

In: Annales de Chirurgie, Vol. 45, No. 4, 1991, p. 306-312.

Research output: Contribution to journalArticle

Rea, S, Recchia, F, Belli, L & Jaffrain-Rea, ML 1991, 'Prévention des métastases hépatiques dans les cancers du côlon opérés radicalement.', Annales de Chirurgie, vol. 45, no. 4, pp. 306-312.
Rea, S. ; Recchia, F. ; Belli, L. ; Jaffrain-Rea, M. L. / Prévention des métastases hépatiques dans les cancers du côlon opérés radicalement. In: Annales de Chirurgie. 1991 ; Vol. 45, No. 4. pp. 306-312.
@article{cac249c0831e43cd9a822b36aadce869,
title = "Pr{\'e}vention des m{\'e}tastases h{\'e}patiques dans les cancers du c{\^o}lon op{\'e}r{\'e}s radicalement.",
abstract = "The prognosis of colon cancer, after curative resection, is mainly related to the outcome of metastases, and especially of liver metastases. It is generally accepted that adjuvant medical therapy is important in order to prevent the incidence of metastatic recurrences. The aim of the present review is to analyse the conclusions of the main recent randomized trials assessing the comparative value of different adjuvant protocols. The results obtained using either systemic infusion, the classical one, or intraportal infusion, which is mainly designed to prevent liver metastases, are reported. On the basis of the review, we can conclude that: adjuvant chemotherapy using combined drugs (MF, MOF) did not prove to be more active than 5-FU alone. The beneficial action of a combined 5-FU + levamisole regimen has been clearly demonstrated for patients with a Dukes C tumour. According to a unique and limited trial, intraportal adjuvant therapy has been shown to be effective for patients with Dukes B tumours, but this remains to be confirmed. On the basis of the present data, new adjuvant programs using combined chemotherapeutic and immunotherapeutic coupounds, and combined systemic and loco-regional infusion, could be developed.",
author = "S. Rea and F. Recchia and L. Belli and Jaffrain-Rea, {M. L.}",
year = "1991",
language = "Francese",
volume = "45",
pages = "306--312",
journal = "Annales de Chirurgie",
issn = "0003-3944",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Prévention des métastases hépatiques dans les cancers du côlon opérés radicalement.

AU - Rea, S.

AU - Recchia, F.

AU - Belli, L.

AU - Jaffrain-Rea, M. L.

PY - 1991

Y1 - 1991

N2 - The prognosis of colon cancer, after curative resection, is mainly related to the outcome of metastases, and especially of liver metastases. It is generally accepted that adjuvant medical therapy is important in order to prevent the incidence of metastatic recurrences. The aim of the present review is to analyse the conclusions of the main recent randomized trials assessing the comparative value of different adjuvant protocols. The results obtained using either systemic infusion, the classical one, or intraportal infusion, which is mainly designed to prevent liver metastases, are reported. On the basis of the review, we can conclude that: adjuvant chemotherapy using combined drugs (MF, MOF) did not prove to be more active than 5-FU alone. The beneficial action of a combined 5-FU + levamisole regimen has been clearly demonstrated for patients with a Dukes C tumour. According to a unique and limited trial, intraportal adjuvant therapy has been shown to be effective for patients with Dukes B tumours, but this remains to be confirmed. On the basis of the present data, new adjuvant programs using combined chemotherapeutic and immunotherapeutic coupounds, and combined systemic and loco-regional infusion, could be developed.

AB - The prognosis of colon cancer, after curative resection, is mainly related to the outcome of metastases, and especially of liver metastases. It is generally accepted that adjuvant medical therapy is important in order to prevent the incidence of metastatic recurrences. The aim of the present review is to analyse the conclusions of the main recent randomized trials assessing the comparative value of different adjuvant protocols. The results obtained using either systemic infusion, the classical one, or intraportal infusion, which is mainly designed to prevent liver metastases, are reported. On the basis of the review, we can conclude that: adjuvant chemotherapy using combined drugs (MF, MOF) did not prove to be more active than 5-FU alone. The beneficial action of a combined 5-FU + levamisole regimen has been clearly demonstrated for patients with a Dukes C tumour. According to a unique and limited trial, intraportal adjuvant therapy has been shown to be effective for patients with Dukes B tumours, but this remains to be confirmed. On the basis of the present data, new adjuvant programs using combined chemotherapeutic and immunotherapeutic coupounds, and combined systemic and loco-regional infusion, could be developed.

UR - http://www.scopus.com/inward/record.url?scp=0025830025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025830025&partnerID=8YFLogxK

M3 - Articolo

C2 - 2064293

AN - SCOPUS:0025830025

VL - 45

SP - 306

EP - 312

JO - Annales de Chirurgie

JF - Annales de Chirurgie

SN - 0003-3944

IS - 4

ER -